Infertility Treatment Market

Executive Summary

Infertility Treatment Market was valued at US $1.62 billion in 2021 and is projected to grow at 8.06% CAGR over the forecast period to reach US $2.58 billion by 2027. Infertility Treatment Market represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $0.96 billion opportunity in 2027 over 2021.

Infertility Treatment from Consainsights analyses the Infertility Treatment Market in the Life Sciences industry over the forecast period to 2027.

Infertility Treatment research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Infertility Treatment segmentation includes Product, Procedure, Patient Type, End User, Region and Geography.

Based on the Product, the Infertility Treatment analysis covers Equipment, Media & Consumables, Accessories.

In Product segment, Equipment segment has highest cagr growth of 7.13%.

Based on the Procedure, the Infertility Treatment analysis covers Assisted Reproductive Technology, Artificial Insemination, Fertility Surgery, Other Infertility Treatment Procedures.

In Procedure segment, Assisted Reproductive Technology segment has highest cagr growth of 7.13%.

Based on the Patient Type, the Infertility Treatment analysis covers Female Infertility Treatment, Male Infertility Treatment.

In Patient Type segment, Female Infertility Treatment segment has highest cagr growth of 7.13%.

Based on the End User, the Infertility Treatment analysis covers Fertility Centers, Hospitals and Surgical Clinics, Research Institutes, Cryobanks.

In End User segment, Fertility Centers segment has highest cagr growth of 7.13%.

Based on the Region, the Infertility Treatment analysis covers North America, Europe, Asia Pacific, Rest of the World.

In Region segment, North America segment has highest cagr growth of 7.13%.

Based on the region, the Infertility Treatment analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Cook Group Incorporated, Esco Micro Pte. Ltd., Genea Limited, Hamilton Throne, Ltd., Ihmedical A/S, Irvine Scientific (A Member of Jx Holdings Group), IVFTech Aps, Kitazato Corporation, Medgyn Products, Inc., Rocket Medical PLC, Somatex Medical Technologies GmbH, The Baker Company, Inc., The Cooper Companies, Inc., Thermo Fisher Scientific, Vitrolife Ab, Zeiss Group and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Equipment segment has the highest revenue of US $0.85 billion and is expected to grow at CAGR of 7.13% by 2027 Equipment segment has highest cagr growth of 7.13%.

Equipment

Equipment segment was valued at US $0.73 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $1.36 billion by 2027. Equipment segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.50 billion opportunity in 2027 over 2021.

Media & Consumables

Media & Consumables segment was valued at US $0.43 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.81 billion by 2027. Media & Consumables segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.30 billion opportunity in 2027 over 2021.

Accessories

Accessories segment was valued at US $0.23 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.42 billion by 2027. Accessories segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.16 billion opportunity in 2027 over 2021.

Procedure

Introduction

In 2021, Assisted Reproductive Technology segment has the highest revenue of US $0.95 billion and is expected to grow at CAGR of 7.13% by 2027 Assisted Reproductive Technology segment has highest cagr growth of 7.13%.

Assisted Reproductive Technology

Assisted Reproductive Technology segment was valued at US $0.82 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $1.52 billion by 2027. Assisted Reproductive Technology segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.56 billion opportunity in 2027 over 2021.

Artificial Insemination

Artificial Insemination segment was valued at US $0.34 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.63 billion by 2027. Artificial Insemination segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.23 billion opportunity in 2027 over 2021.

Fertility Surgery

Fertility Surgery segment was valued at US $0.17 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.32 billion by 2027. Fertility Surgery segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.12 billion opportunity in 2027 over 2021.

Other Infertility Treatment Procedures

Other Infertility Treatment Procedures segment was valued at US $0.06 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.11 billion by 2027. Other Infertility Treatment Procedures segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.

Patient Type

Introduction

In 2021, Female Infertility Treatment segment has the highest revenue of US $0.86 billion and is expected to grow at CAGR of 7.13% by 2027 Female Infertility Treatment segment has highest cagr growth of 7.13%.

Female Infertility Treatment

Female Infertility Treatment segment was valued at US $0.74 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $1.37 billion by 2027. Female Infertility Treatment segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.51 billion opportunity in 2027 over 2021.

Male Infertility Treatment

Male Infertility Treatment segment was valued at US $0.65 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $1.21 billion by 2027. Male Infertility Treatment segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.45 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Fertility Centers segment has the highest revenue of US $0.66 billion and is expected to grow at CAGR of 7.13% by 2027 Fertility Centers segment has highest cagr growth of 7.13%.

Fertility Centers

Fertility Centers segment was valued at US $0.57 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $1.06 billion by 2027. Fertility Centers segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.39 billion opportunity in 2027 over 2021.

Hospitals and Surgical Clinics

Hospitals and Surgical Clinics segment was valued at US $0.45 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.84 billion by 2027. Hospitals and Surgical Clinics segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.31 billion opportunity in 2027 over 2021.

Research Institutes

Research Institutes segment was valued at US $0.22 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.41 billion by 2027. Research Institutes segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.15 billion opportunity in 2027 over 2021.

Cryobanks

Cryobanks segment was valued at US $0.15 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.27 billion by 2027. Cryobanks segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $0.83 billion and is expected to grow at CAGR of 7.13% by 2027 North America segment has highest cagr growth of 7.13%.

North America

North America segment was valued at US $0.71 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $1.32 billion by 2027. North America segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.49 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $0.39 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.73 billion by 2027. Europe segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.27 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $0.19 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.36 billion by 2027. Asia Pacific segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.13 billion opportunity in 2027 over 2021.

Rest of the World

Rest of the World segment was valued at US $0.09 billion in 2019 and is projected to grow at 7.13% CAGR over the forecast period to reach US $0.18 billion by 2027. Rest of the World segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.